Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma

SIMPLE SUMMARY: In stage IV melanoma, the combination of ipilimumab and nivolumab improves outcomes compared to single agents. However, it bears an important financial impact on the healthcare system. In this manuscript, we analyze the costs related to the ipilimumab–nivolumab combination, focusing...

Descripción completa

Detalles Bibliográficos
Autores principales: Gautron Moura, Bianca, Gerard, Camille L., Testart, Nathalie, Caikovski, Marian, Wicky, Alexandre, Aedo-Lopez, Veronica, Berthod, Grégoire, Homicsko, Krisztian, Prior, John O., Dromain, Clarisse, Kandalaft, Lana E., Cuendet, Michel A., Michielin, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817856/
https://www.ncbi.nlm.nih.gov/pubmed/36612030
http://dx.doi.org/10.3390/cancers15010031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817856/
https://www.ncbi.nlm.nih.gov/pubmed/36612030
http://dx.doi.org/10.3390/cancers15010031

Ejemplares similares